Apotex launches first Nasonex generic

TORONTO — Apotex announced Tuesday that it had launched its generic of Merck’s Nasonex (mometasone furoate monohydrate) in the United States. Apotex’s drug is the first generic of the nasal congestion treatment. 

 

“We are very pleased to make a more affordable version of this important allergy medicine available to the US public,” Apotex president and CEO Dr. Jeremy B. Desai said. “The amount of work required by all stakeholders to enable the launch of a first generic of this complexity cannot be overstated, and we appreciate the role of everyone involved, including the FDA who provided steady guidance throughout the development process.”

 

Nasonex had annual sales of $955.5 million for the 12 months ended January 2016, according to IMS Health.